Utrecht-based biotech startup CryoCloud announced that it has secured €500,000 in a pre-seed funding round led by Nina Capital, with significant contributions from the Utrecht Health Seed Fund and ROM Utrecht Region.
The company will use the funds to accelerate growth and build partnerships with leading companies and key opinion leaders. The Dutch company will also use the capital to expand the platform’s capabilities, better support scientists and streamline data analysis.
Robert Englemeier, CEO of CryoCloud, says: “The Cryo-EM environment and throughput have evolved significantly over the past six years, but the way we analyze data has remained the same, creating bottlenecks and barriers to entry. Our mission is to make cryo-EM more accessible and streamline the research process, which is now possible with our platform.”
CryoCloud: Data analysis platform development
Founded in 2021 by Robert Englmeier, Ilja Gubins and Boy Persoon, CryoCloud has developed cryoEM, a proprietary data analytics platform.
Our cloud-based data analysis platform enables rapid, scalable determination of 3D protein structures for use in drug discovery.
As a result, it addresses important challenges facing the scientific community, including the high cost, complexity, and inefficiencies associated with existing cryo-EM computing infrastructure.
By providing scalable cloud storage and data analysis workflows through a user-friendly web app, the Dutch company is making advanced research tools more accessible to scientists around the world.
The company’s cloud-based data analytics platform is accessible through a subscription-based web application and is used by scientists at universities, biotechnology, and cryo-EM facilities worldwide.
CryoCloud is headquartered in Utrecht, Netherlands, where Robert Englemeier and Ilja Gubins performed their PhDs in applied and computational cryoEM, respectively.
investor
Nina Capital is a specialist venture capital firm investing exclusively at the intersection of healthcare and technology.
Marta-Gaia Zanchi, Founder and Managing Partner of Nina Capital, said: “CryoCloud’s innovative approach to leveraging cloud technologies in cryo-EM is not only a major step forward in structural biology, but also a testament to the transformative power of digital solutions in the life sciences. sector.”
Utrecht Health Seed Fund (UHSF) is an early-stage life sciences and health investment fund based in Utrecht, Netherlands. We focus on scalable technologies at early development stages in life sciences (therapeutics and diagnostics), medical devices, digital health, and animal health.
“We are pleased to invest in CryoCloud’s solution to make the complex and costly CryoEM analysis process more accessible to researchers,” said Timo Koopmans, Investment Manager at Utrecht Health Seed Fund. “Their platform has the potential to significantly expand the use of CryoEM in life sciences.”